Novel intracellular transport-refractory mutations in KCNH2 identified in patients with symptomatic long QT syndrome

Daisuke Fukumoto1, Wei-Guang Ding2, Yuko Wada1

  • 1Department of Cardiovascular and Respiratory Medicine, Shiga University of Medical Science, Otsu, Shiga, Japan.

Journal of Cardiology
|November 18, 2017
PubMed
Abstract

Insights

Two novel KCNH2 mutations disrupt Kv11.1 channel transport, causing nonfunctional channels in long QT syndrome (LQTS) type 2. Low temperatures partially restored one mutation

Area of Science:

  • Genetics and Molecular Biology
  • Cardiovascular Physiology
  • Channelopathies

Background:

  • Missense mutations in KCNH2, encoding the Kv11.1 channel, are a primary cause of long QT syndrome (LQTS) type 2.
  • These mutations often impair the intracellular transport of Kv11.1 channels to the cell surface.

Purpose of the Study:

  • To investigate the functional consequences of two newly identified KCNH2 missense mutations.
  • To elucidate the impact of these mutations on Kv11.1 channel trafficking and function.

Main Methods:

  • Genetic screening of LQTS probands identified two novel KCNH2 mutations.
  • Electrophysiological analysis using patch-clamp on transfected cells.
  • Immunostaining and confocal microscopy to assess Kv11.1 localization.
  • Investigated rescue strategies including low-temperature incubation and pharmacological agents.

Main Results:

  • Two novel mutations, G785D and T826I, were identified.
  • Both mutations resulted in nonfunctional homozygous channels and reduced current density in heterozygous states.
  • Mutations were transport-refractory; low-temperature incubation rescued Kv11.1-T826I trafficking but not G785D.
  • Pharmacological rescue attempts with E-4031 or dofetilide were unsuccessful.

Conclusions:

  • The identified KCNH2 mutations disrupt Kv11.1 intracellular transport.
  • These mutations lead to loss-of-function, explaining LQTS type 2 phenotypes.
  • Differential rescue potential exists, with low temperature partially restoring Kv11.1-T826I function.

Related Concept Videos

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
2.6K
Voltage-gated Ion Channels01:26

Voltage-gated Ion Channels

Voltage-gated ion channels are transmembrane proteins that open and close in response to changes in the membrane potential. They are present on the membranes of all electrically excitable cells such as neurons, heart, and muscle cells.
Generally, all voltage-gated ion channels have a 'voltage-sensing domain' that spans the lipid bilayer. The charged residues in the sensor move in response to the membrane potential changes that open the channel allowing ions movement. There are several types of...
11.2K
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
3.6K
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
19
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
732
Non-gated Ion Channels01:24

Non-gated Ion Channels

Ion channels are specialized proteins on the plasma membrane that allow charged ions to pass down their electrochemical gradient. Their main function is to maintain the membrane potential which is critical for cell viability. These channels are either gated or non-gated and can transport more than a thousand ions within milliseconds for the cellular event to occur.
Compared to the gated ion channels, the non-gated channels, also known as leakage or passive channels, have no gating mechanism....
8.3K